Welcome to our dedicated page for DRUGS MADE IN AMER ACQUISITION SEC filings (Ticker: DMAAU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Drugs Made In America Acquisition Corp. (DMAAU) is a blank check company whose securities are registered in connection with its initial public offering on the Nasdaq Global Market. Although no specific SEC filings are listed here in this dataset, the company’s public statements reference a registration statement on Form S‑1 that was declared effective by the U.S. Securities and Exchange Commission in connection with its IPO, along with a post‑effective amendment.
As a SPAC and shell company in the financial services sector, DMAAU’s SEC filings are expected to describe its structure as a Cayman Islands exempted company, the terms of its units, ordinary shares, and rights, and the general framework for its planned business combination activities. These documents typically outline the company’s intention to pursue a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses.
The company has stated that it intends to focus its search for a target in the pharmaceutical industry, with an emphasis on businesses that may help mitigate risks in the U.S. medical supply chain by supporting strategic on‑shoring of advanced domestic manufacturing technologies for critical drugs. Over time, investors can expect that key SEC reports, such as annual and quarterly reports and any merger‑related filings, would provide more detail on its acquisition progress and any proposed business combination.
On Stock Titan’s SEC filings page, users can access DMAAU’s regulatory documents as they become available through EDGAR, along with AI‑generated summaries that explain the structure and implications of each filing. This includes registration statements and, if and when they are filed, ongoing reports and any transaction‑related disclosures that describe the company’s efforts to complete an initial business combination.
Karpus Management reported beneficial ownership of 2,744,109 common shares of Drugs Made In America Acquisition Corp., equal to 8.19% of the class. The shares are held directly in accounts managed by Karpus, which states it has sole voting and sole dispositive power over the shares. Karpus is a New York-formed registered investment adviser that notes it is controlled by City of London Investment Group plc but maintains informational barriers so that voting and investment decisions are made independently by Karpus. The filing indicates the position is held in the ordinary course of business and not for the purpose of changing control of the issuer.